-
Flamengo secure 0-0 draw in La Plata in Copa Libertadores semi
-
Wong weighs haze prosecutions as Singapore air quality worsens
-
The final lap? Two days on the campaign trail with Trump
-
Brush fire prompts an evacuation order along Los Angeles coast
-
Asian stocks rise as tech bounces from rout, eyes on Warsh
-
'Mixed feelings': AI cracks centuries-old ciphers
-
Saudi organisers say 2027 Asian Cup 'on schedule' after attacks
-
Le Pen looms large as Macron enters final months on EU stage
-
Right-wing Brazil influencers on 'mission' to seal Bolsonaro win
-
Three children, one teacher killed in Oregon elementary school shooting
-
Using AI to help find Mexico's legions of missing children
-
Man Utd teetering towards crisis as Man City cloud hangs over Premier League
-
Fiji to deploy solar-powered Australian military drones at sea
-
Trump's new press secretary defends 'lawyer' title
-
'Multiple victims' in Oregon elementary school shooting, police say
-
Wallabies coach has 'faith' as All Blacks juggernaut awaits
-
'Multiple victims' in Oregon elementary school shooting: police
-
Ailing UK director Mike Leigh wishes he could make '100 more films'
-
ChangeNOW Announces NOW AI After Resolving Website Integration Vulnerability
-
Pixagram Announces Free Account Creation for 250 New Users Daily Through 2026
-
Argentine demonstration over education cuts ends in clashes
-
Macron warns urgent to strike EU budget deal before French vote runup
-
Argentine protesters, police clash at demo over university funding
-
Zelensky rallies European allies as Trump ties slump
-
US stocks end higher as AI shares stabilize
-
Guardians edge Rays to seize MLB playoff series lead
-
School roof collapse kills 32 children, teacher in Pakistan
-
Trump scraps plan to livestream execution after fierce backlash
-
Lyon down Palace in Europa League, Sunderland leave it late
-
Martinez apologises for outburst at Man Utd hierarchy
-
UniCredit says receives ECB green light for Commerzbank takeover
-
Houthis launch deadly attack on presidential palace in Yemen's Aden
-
New York City pension fund asks Anthropic to delay IPO
-
Brazil forward Antony says home burgled during Betis match
-
Venezuela's Maduro denies US torture charges as 'false accusations'
-
Ravens face familiar foe in Browns coach Monken
-
Somalia sets May presidential election despite insecurity
-
France, Germany reach deal on future of car industry
-
Chelsea's Caicedo eager to be more of a leader
-
Carney campaigns for Canadian unity before Alberta secession vote
-
Rahm reaches separation deal with LIV in bankruptcy court
-
ATP proposes rankings system changes, extra player bonuses
-
UN chief urges nations to end 'war on nature'
-
Russell Brand was 'monster-like', alleged victim tells UK court
-
Newcastle boss Jaissle says Fernandez-Pardo just needs a goal
-
Crowded Launches Crowded MCP, Bringing Nonprofit Financial Operations Into ChatGPT and Claude
-
Infantino offers apology but 'no answers' at FIFA meeting over World Cup plan
-
Albanian PM condemns 'chaos' as violent unrest spreads
-
Don't exclude Turkey from 'Made in Europe' plan: minister to AFP
-
Italian football suffers new blow with Champions League misery
Brazilian ritual root gets second life as potential anti-depressant
Long used in Indigenous Brazilian rituals, the jurema preta plant, which contains a potent psychedelic, is gaining ground as a potential treatment for depression.
At street stalls where medicinal herbs are sold, customers can buy the plant's root which contains dimethyltryptamine (DMT), a hallucinogenic substance that researchers say could be used to alleviate symptoms.
Following instructions he found on the internet, Guaracy Carvajal extracted DMT at home in 2016 from roots he bought on the street.
The 31-year-old software programmer, who had tried various treatment for chronic depression he has suffered since adolescence, said the drug makes it "feel like you've solved something in your life."
Physicist Draulio Araujo, who has conducted extensive research on the drug, said "the response is rapid. One day after treatment, (patients) already showed a significant improvement in their depression symptoms."
Yet he also warned that it "is not a magic cure" and that psychedelics "are not for everyone."
As a researcher at the Brain Institute of the Federal University of Rio Grande do Norte, Araujo and his team treated 14 people with the drug for six months.
The patients inhaled vaporized DMT, under medical supervision.
"It's common for our patients to say that something changed, that a key opened something," he said.
His patients also received psychological therapy, and some continued with conventional pharmaceutical drugs.
Neuroscientist Fernanda Palhano-Fontes, also of the Brain Institute, said "we have patients who improve significantly, others who don't improve at all."
Araujo's findings were published in the scientific journal Nature in April. In 2024, he published another study with promising results in the journal Psychedelic Medicine.
As for Carvajal, who stopped using jurema preta some time ago, he said the drug really allows a person to "start to have a lighter life."
It helped him get through a time when he was in "a state of questioning myself" about "work, day-to-day life," he said.
- Spiritual channels -
Brazil occupies a fairly prominent place in DMT research due to the substance's prominence in society, Araujo said.
While there is no ban on the cultivation or possession of jurema, which is also known as Mimosa tenuiflora, consumption of DMT is prohibited, except for religious and scientific use.
Jurema's roots are combined with other plants in a wine-like beverage that is consumed at rituals that include dancing and drums, part of Indigenous tradition in northeast Brazil where the plant grows.
"It's not hallucination," said Joyce Souza, a young woman attending a jurema ceremony in Planaltina, on the outskirts of Brasília.
"My spiritual channels become more accessible, I can communicate better with myself," Souza said.
Gathered in a house courtyard and dressed in white, the group of mostly novices waited for more seasoned practitioners to enter a trance and bring messages from ancient spirits.
Meanwhile, back in the lab, Araujo is hoping to expand his DMT research to a study of 100 patents.
"Let's say that in five years we'll have... a clear picture on when it will reach a real clinical setting," he said.
F.AbuZaid--SF-PST